AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05209282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional physiotherapy program
Description: Individuals in this group will only receive a conventional physiotherapy program.
Study NCT05001802 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transverse scan, in-plane, posterior- anterior quadratus lumborum block
Description: transverse scan, in-plane, posterior- anterior quadratus lumborum block The patients will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
Study NCT05001802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paramedian sagittal longitudinal scan, in-plane, caudal-cranial quadratus lumborum block
Description: The patients will receive the transmuscular quadratus lumborum block before surgery using the paramedic sagittal longitudinal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
Study NCT06437327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrotherapy
Description: Hot pack for 10 minutes Interferential Current (IFC) for 10 minutes
Study NCT05233774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic MSC
Description: An allogeneic bone marrow-derived medicinal signaling cell (MSC) formulation
Study NCT05233774 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06287359 — intervention group
Intervention type: OTHER
Intervention: individual interviews
Description: Qualitative research with individual interviews
Study NCT04978493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 706321
Description: BI 706321
Study NCT04978493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab
Description: ustekinumab
Study NCT04978493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ustekinumab
Description: ustekinumab
Study NCT04978493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06542094 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain stimulation
Description: All subjects will receive bilateral surgical implantation of DBS system.
Study NCT06276894 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Motek C-Mill™ treadmill
Description: We will enroll 10 to 15 participants to participate in a VR treadmill training session while wearing an fNIRS cap.
Study NCT06276894 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: training session with and without VR wearing the fNIRS cap
Description: training session with and without VR wearing the fNIRS cap
Study NCT05531539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WELMO sensors vest
Description: Wearing of a vest equipped with lung auscultation and EIT sensors for signal acquisition and transmission
Study NCT04818346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: INCB054707 will be administered once daily
Study NCT04818346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo or INCB054707 will be administered once daily
Study NCT05309161 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Crassocephalum rabens extract
Description: dosage: a capsule (180 mg)/day; duration: 1 month
Study NCT05309161 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Crassocephalum rabens extract
Description: dosage: a capsule (180 mg)/day; duration: 1 month
Study NCT02540200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BST-CarGel
Description: BST-CarGel is a scaffolding material after microfracture treatment is performed in order to treat the chondral lesions. It assists in the repair process by stabilizing the clot in the cartilage lesion via adhesion and inhibition of clot retraction.
Study NCT02540200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture
Description: It is a bone marrow stimulation technique, and the standard treatment for chondral lesions of the hip joint.
Study NCT02540200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: It is a bone marrow stimulation technique, and the standard treatment for chondral lesions of the hip joint.
Study NCT05851482 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High resolution manometry
Description: Standard chicago classification 4.0 HRM protocol
Study NCT06336096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suzetrigine
Description: Tablet(s) for oral administration.
Study NCT06336096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suzetrigine
Description: Tablet(s) and Suspension for oral administration.
Study NCT06437327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active release technique
Description: Active release technique is applied (patient is prone lying with knee flexed, Pressure is applied on taut band and patient is asked to move the leg in internal rotation to achieve maximal lengthening) Repetitions 5 to 7 times hold for 5 to 20 seconds
Study NCT06437327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hold relax technique
Description: This technique is applied while the patient is in supine lying with one leg crossed over the other Patient is instructed to contract the piriformis against the manual resistance for 5 to 10 secs Then 15 secs of passive stretch is given repetitions x 5 times
Study NCT06448845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm intravenous regional anesthesia
Description: After placement of the upper arm and forearm tourniquets and exsanguination of the limb distal to the cuff by applying an Esmarch's bandage starting from the fingertips, the arm tourniquet cuff is inflated to a pressure of 250 mmHg. The double arm cuff pneumatic pressure tourniquet is placed immediately above the elbow crease and on the top of a circumferentially placed cotton cast padding before inflation. Subsequently, tourniquet failure is ruled out by observing the absence of distal circulation and 40 ml 0.5% lidocaine is slowly injected through the intravenous cannula on the dorsum of the hand. The tourniquet remained inflated for 60 minutes from injection of lidocaine to reduce the risk of local anesthetic systemic toxicity (LAST)
Study NCT06448845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm IVRA block
Description: After placement of the forearm double tourniquet and exsanguination of the limb distal to the cuff by applying an Esmarch's bandage starting from the fingertips, the forearm tourniquet cuff is inflated to a pressure of 250 mmHg. The forearm tourniquet will be placed 5 cm distal to the medial epicondyle of the humerus and on the top of a circumferentially placed cotton cast. Subsequently, tourniquet failure is ruled out by observing the distal circulation and 25 ml 0.5% lidocaine is slowly injected through the intravenous cannula on the dorsum of the hand.
Study NCT05589610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EQ101
Description: EQ101, 2 mg/kg, once weekly dosing, for a total of 24 doses
Study NCT05064488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive evobrutinib film-coated tablet, twice daily under fed conditions from Days 4 to 12 in Part 1 and from Days 2 to 8 in Part 2 of the study.
Study NCT05064488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Participants will receive digoxin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
Study NCT05064488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive metformin oral solution under fed conditions, once a day on Day 1 and Day 10 in Part 1.
Study NCT05064488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will receive rosuvastatin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
Study NCT05064488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Participants will receive sumatriptan tablet under fed conditions, once a day on Day 1 and Day 8 in Part 2.
Study NCT06479538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post isometric relaxation
Description: 17 participants will be in experimental group A giving them Post isometric relaxation of Quadratus lumborum for four weeks, measuring all values before giving them protocol and after protocol.
Study NCT06479538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post facilitation stretching
Description: 17 participants will be in experimental group A giving them Post facilitation stretching of Quadratus lumborum for four weeks, measuring all values before giving them protocol and after protocol.
Study NCT06530953 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigator Model
Description: The patient navigator model is an evidence-based intervention to improve access to healthcare services.
Study NCT05647447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osanetant
Description: Osanetant 200 mg orally, twice per day
Study NCT06536790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hang clean training
Description: This include hang clean training thrice a week for twelve weeks
Study NCT06536790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: half squat training
Description: This include half squat training thrice a week for twelve weeks
Study NCT05526638 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ultraviolet phototherapy
Description: thrice weekly sessions of ultraviolet phototherapy
Study NCT04953442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit 24
Description: This 12-week goal-setting intervention will test the feasibility of using a Fitbit watch and motivational text messaging to improve physical activity and sleep in Hispanic youth (14-16 years of age) with obesity. Youth will be prompted to set weekly steps per day and hours of sleep per night goals. Text messages will be grounded in the Self-Determination Theory and will provide evidence-based strategies, support, and motivation to encourage youth to meet their goals.
Study NCT05940181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XH001+ sintilimab
Description: During treatment period, subjects will receive 6 cycles of XH001+ sintilimab, followed by sintilimab monotherapy (sintilimab will be administered for up to 18 cycles or for 1 year, whichever comes first).
Study NCT06331221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle fatigue Protocol
Description: Four experimental conditions consisting of different local muscle fatigue protocols performed in the isokinetic dynamometer in random order, with at least one week of interval between them.
Study NCT05059691 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study NCT05059691 — intervention group
Intervention type: PROCEDURE
Intervention: Transbronchial Cryobiopsy Guided by Three-Dimensional Fluoroscopy
Description: Undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy
Study NCT05061121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined effect
Description: Compare the short- and mid-term effects of Mulligan's SNAGs, Myofascial release, and their combination on pain intensity, pain pressure sensitivity, cervical function, range of motion (ROM) and postural stability in CNSNP patients
Study NCT05824468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Injectable solution
Study NCT05824468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Capsule
Study NCT04768829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moringa oleifera leaf 10mg/100ml
Description: ear drops
Study NCT04768829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ear Drop
Description: plain ear drop formulation without moringa
Study NCT04800900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical intervention
Description: A pharmacist will analyse patient's prescription, identify if there is prescribing omission and inappropriated drug prescribed and when necessary will require to doctors deprescribe or introduce or remove prescribed drugs
Study NCT05640583 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hygieacare System
Description: The device is an FDA cleared colon irrigation device, it will be used according to clearance. The sampling of the colon effluent sampled is the are of study.
Study NCT05640583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hygieacare System
Description: The device is an FDA cleared colon irrigation device, it will be used according to clearance. The sampling of the colon effluent sampled is the are of study.
Study NCT05221385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentulizumab
Description: Gentulizumab is administered IV once a week, with every 4 weeks as an administration cycle.
Study NCT04626791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study NCT04626791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC
Study NCT04626791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT05587478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-323
Description: Oral administration
Study NCT05587478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match EDP-323, oral administration
Study NCT06530043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Senobi exercises
Description: Senobi exercise began with the comfortable sitting of participants with slow inhalation, filling the lungs for a count of 4-5 seconds and holding the breath for 2-3 seconds.
Study NCT06530043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jacobsons Muscular relaxation exercises
Description: Jacobsons Muscular relaxation exercises started by tensing the muscles in the toes and then moving up the body tensing and relaxing each muscle group in turn (feet and toes, calves, thighs, hips, lower back, upper back, shoulders, arms, hands, neck, and head) and hold it for 5-7 seconds and released it for 5-7 seconds.
Study NCT04765852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dose probiotic supplement
Description: One probiotic stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
Study NCT04765852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose probiotic supplement
Description: One probiotic stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
Study NCT04765852 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo stick pack will be dissolved in 10 mL lukewarm formula milk or breastmilk at body temperature. The dissolved supplement will be fed orally, preferably in the morning, starting on Day 1 until Day 56.
Study NCT04626791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT04626791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT04626791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT04626791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04626791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab and Hyaluronidase Human
Description: Given IV
Study NCT05876208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAND Connect's VirtuaCare™ platform
Description: Band Connect provides a medical-grade and condition-specific platform that augments the clinician workflow by extending the in-clinic MSK rehabilitation experience into the patient's home - leading to higher quality personalized treatment and increased adherence with enhanced economics and reimbursement for the clinic.
Study NCT05876208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Physical Therapy
Description: Standard of care physical therapy without the use of the BAND CVCP
Study NCT05742399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid NanoGel
Description: Hyaluronic acid nanoparticles (2%)
Study NCT05742399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: conventional gel having the same color, form and packaging
Study NCT06320899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpineShape System IV straight rod elastic
Description: Implantation of SpineShape System IV straight rod elastic
Study NCT06320899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpineShape System IV straight rod medium
Description: Implantation of SpineShape System IV straight rod medium (mid-flex)
Study NCT06320899 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpineShape System IV straight rod stiff
Description: Implantation of SpineShape System IV straight rod stiff (low-flex)
Study NCT05580549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Alcohol biomarker Phosphatidylethanol (PEth)
Description: The prevalence of hazardous alcohol use will be mapped through the biomarker PEth and the questionnaire AUDIT.
Study NCT05138393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active self-corrective exercises
Description: Scoliosis specific exercises with an Active self-corrective approach. Non-specific physical activity 60 minutes per day.
Study NCT05138393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Non-specific physical activity 60 minutes per day.
Study NCT04385082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Cannabis
Description: Smoked cannabis with THC
Study NCT04385082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cannabis
Description: Placebo smoked cannabis (no THC)
Study NCT05108194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Personalized Sleep Intervention
Description: All participants will be enrolled in the intervention to evaluate the feasibility and acceptability of the SMS-PSI. After the data training and validation phase, participants will be provided with at least one and up to three daily text messages that offer users a specific strategy based on strategies from CBTi. All participants will have access to a user dashboard, which is a web-app that includes personalized sleep-tracking information and the opportunity to customize their messaging. The person-level acceptability and adherence to the sleep strategies will be evaluated via self-report endorsement from daily diary and whether users added suggestions to their calendars. Both adherence and acceptability will be collected and integrated with the selection algorithm to optimize subsequent SMS suggestions.
Study NCT05408494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamified behavioral weight loss treatment
Description: 12-month mHealth fully-gamified version of the same program, comprised of a behavior change program with digital reinforcers for attainment of streaks and milestones, and an integrated neurotraining video game
Study NCT05408494 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth behavioral weight loss treatment
Description: a 12-month mHealth weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets, physical activity and a control (sham) non-game neurotraining
Study NCT05408494 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: mHealth behavioral weight loss treatment
Description: a 12-month mHealth weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets, physical activity and a control (sham) non-game neurotraining
Study NCT05320614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-Based Education
Description: Web-Based Education Information about the operation that the child will undergo; animation films about the hospital, the operating room and the medical equipment to be used; training with presentation including methods of coping with anxiety, fear and pain, postoperative wound care, possible complications in nutrition and nursing care; educational games Education with Therapeutic Play Method Training with the therapeutic game method for 30-45 minutes in the game room in the service one day before the surgery
Study NCT05320614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine maintenance Training
Description: Explaining the routine care given to the child and parent in the control group by the pediatric surgery nurse in the service.
Study NCT04468178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total joint arthroplasty of the glenohumeral joint
Description: The arthroplasty of the glenohumeral joint will be performed as an anatomical reconstruction after primary or post-traumatic osteoarthritis.